TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20562702
Drug: TAK-242 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-242 2.4 mg/kg/day
Study: 15684116
Drug: Amoxicillin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (60 mg/kg daily for 10 days)
Study: 15684116
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and Placebo
Study: 11925355
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg of thyroxine daily
Study: 7895394
Drug: Supervised training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised training twice a week for 3 months
Study: 3075410
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of tripamide
Study: 3075410
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of hydrochlorothiazide
Study: 11307810
Drug: Argatroban (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (higher doses)
Study: 11307810
Drug: Co-therapy (argatroban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-therapy (argatroban and warfarin)
Study: 23075570
Drug: Early discharge
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early discharge from hospital after 3 days inpatient treatment with home visits by generic community nurses
Study: 19858233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eight biomarkers (von Willebrand factor antigen, surfactant protein D, tumor necrosis factor receptor‐1, interleukin [IL]‐6, IL‐8, intercellular adhesion molecule‐1, protein C, plasminogen activator inhibitor‐1) and clinical predictors (APACHE III, organ failures, age, underlying cause, alveolar‐arterial oxygen gradient, plateau pressure)
Study: 17885562
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg daily
Study: 15699722
Drug: Meniett device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meniett device treatment (pressure pulses at 6 Hz for 0.6 seconds, oscillating between 0.4 and 1.2 kPa)
Study: 15699722
Drug: Meniett device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meniett device treatment
Study: 12084604
Drug: First treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: First treatment (both methods pooled)
Study: 12084604
Drug: Second treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second treatment (both methods pooled)
Study: 7638950
Drug: Dihydroergotamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (1 mg) with metoclopramide (10 mg)
Study: 7638950
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg) with metoclopramide (10 mg)
Study: 2495710
Drug: Flecainide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (1 mg/kg bolus over 10 minutes followed by 1.5 mg/kg/hr for 1 hour and then 0.25 mg/kg/hr for 24 hours)
Study: 2495710
Drug: Digoxin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (3 bolus doses: 0.5 mg followed after 6 and 12 hours by 0.25 mg)
Study: 972015
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy started within two months of oophorectomy
Study: 972015
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy started after three years post-oophorectomy
Study: 972015
Drug: Delayed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed estrogen replacement therapy started after six years post-oophorectomy
Study: 30653528
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two high construal level approaches
Study: 28705454
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg ATLG
Study: 28705454
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg ATLG
Study: 25226850
Drug: QAX576 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAX576 (6 mg/kg)
Study: 24429201
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor or H2 blocker
Study: 24429201
Drug: No anti-acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-acid treatment
Study: 21729174
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.1 mL injected intradermally)
Study: 21729174
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.1 mL injected subdermally)
Study: 21729174
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.1 mL injected subcutaneously)
Study: 21729174
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of circulating insulin detemir‐specific antibodies by RIA before and after 3 months
Study: 21729174
Drug: Control (Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Saline injection)
Study: 19555936
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (60 mL) followed by 2 L of PEG-ELS (Prep 3)
Study: 19555936
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (15 g) followed by 2 L of PEG-ELS (Prep 2)
Study: 19555936
Drug: Conventional volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional volume (4 L) of PEG-ELS (Prep 1)
Study: 17145603
Drug: Oral chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chlorambucil
Study: 17145603
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy and autologous or allogeneic stem cell transplantation
Study: 17145603
Drug: Schedules including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedules including non-cross-reactive agents, such as alemtuzumab
Study: 12932242
Drug: 1% coal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% coal tar preparation
Study: 20713833
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream
Study: 2071723
Drug: Amitriptyline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline therapy (25, 50, or 75 mg/day)
Study: 6318346
Drug: Bi‐Profenid tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi‐Profenid tablets (300 mg in 2 daily oral doses)
Study: 6318346
Drug: Profenid capsules
Normalized name: ibuprofen Oral Capsule [Wal-Profen]
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Profenid capsules (300 mg in 3 daily oral doses)
Study: 6318346
Drug: Profenid capsules
Normalized name: ibuprofen Oral Capsule [Wal-Profen]
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Profenid capsules
Study: 6318346
Drug: Bi‐Profenid tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi‐Profenid tablets
Study: 30904207
Drug: Almonds (AS:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds (AS: 56 g/day)
Study: 27759780
Drug: Intravenous Cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Cephazolin (2 g) during anesthetic induction
Study: 24815851
Drug: 20 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg/kg of palifermin
Study: 24815851
Drug: 40 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg/kg of palifermin
Study: 24815851
Drug: 60 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg/kg of palifermin
Study: 17552379
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) intervention plus treatment as usual (mask fitting and information)
Study: 10193216
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia using propofol
Study: 3294189
Drug: gallopamil (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil (150 mg/day)
Study: 3294189
Drug: nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (30 mg/day)
Study: 8201643
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ofloxacin
Study: 2879872
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg norfloxacin
Study: 8201643
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg ciprofloxacin
Study: 2953380
Drug: Ioxaglate (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (320 mg I/ml, osmolality 0.58 ml/kg)
Study: 5440568
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 mug aerosol inhalation)
Study: 5440568
Drug: Isoprenaline (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (1,000 mug aerosol inhalation)
Study: 30845818
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus samidorphan (5 mg)
Study: 30845818
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus samidorphan (10 mg)
Study: 30845818
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus samidorphan (20 mg)
Study: 28803820
Drug: INSIGHT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: INSIGHT (1 unit/day increase in insulin dosage)
Study: 28803820
Drug: EDITION (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDITION (dose adjusted by investigator at least once weekly)
Study: 25867912
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg once daily (OD)
Study: 25867912
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily (BD)
Study: 9743848
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction (Sevoflurane)
Study: 3265624
Drug: New trimethoprim/sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: New trimethoprim/sulfamethoxazole preparation (Kepinol forte, 160 mg of trimethoprim/800 mg of sulfamethoxazole)
Study: 3265624
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (customary in trade and registered according to the AMG 1976)
Study: 27222510
Drug: Lixisenatide once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide once daily
Study: 27222510
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine once daily
Study: 27222510
Drug: Lixisenatide thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide thrice daily
Study: 27222510
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine thrice daily
Study: 22884766
Drug: Bosutinib 100-600
Normalized name: bosutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 100-600 mg coadministered with ketoconazole 400 mg
Study: 22884766
Drug: Bosutinib 600
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 600 mg
Study: 22884766
Drug: Bosutinib 100-600
Normalized name: bosutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 100-600 mg
Study: 20413736
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (AT‐10)
Study: 20413736
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day (AT‐80)
Study: 20413736
Drug: Cholestyramine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 8 g/day plus sitosterol 2.5 g/day
Study: 20413736
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (AT‐10, AT‐80, cholestyramine plus sitosterol)
Study: 17950677
Drug: AZD0865 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0865 25 mg
Study: 17950677
Drug: AZD0865 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0865 50 mg
Study: 17950677
Drug: AZD0865 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0865 75 mg
Study: 10343145
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy regimen of pantoprazole 40 mg (twice daily), clarithromycin 500 mg, and amoxicillin 1,000 mg for 1 week
Study: 10343145
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy regimen of pantoprazole, clarithromycin, and amoxicillin
Study: 6351517
Drug: Varidase solution
Normalized name: DIMETHICONE 30 mg in 1 mL TOPICAL CREAM [AnYi Beauty Varicose Veins Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varidase solution
Study: 31987919
Drug: Add-on strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on strategies (lithium, lamotrigine/carbamazepine, anti-inflammatory drugs)
Study: 15842558
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tolterodine bid
Study: 15842558
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oxybutynin tid
Study: 12554247
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 microg (low dose)
Study: 12554247
Drug: Misoprostol 100
Normalized name: MISOPROSTOL 100MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 100 microg (high dose)
Study: 2132187
Drug: Transfer from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer from porcine to human insulin
Study: 2132187
Drug: Transfer from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer from bovine to human insulin
Study: 31642244
Drug: Individualized intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized intervention through the combination of prenatal and postnatal care
Study: 28537012
Drug: Nutraceutical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical treatment
Study: 23391196
Drug: Both Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both Rivaroxaban and Warfarin
Study: 19656250
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (20 mg ATP during isoproterenol infusion)
Study: 8794413
Drug: Ifosfamide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 2.0 g/m2 days 1-3, mesna 400 mg/m2 at 0, 4, 6 h days 1-3, cisplatin 33 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Study: 8794413
Drug: Etoposide 200
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 200 mg/m2 days 1-3, cisplatin 35 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Study: 2297966
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection (mean 0.975 ml/s)
Study: 2297966
Drug: Rapid injection
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid injection (mean 2.575 ml/s)
Study: 7270561
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 10 mg and hydrochlorothiazide 25 mg (T/H)
Study: 7270561
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg (HCTZ)
Study: 28494595
Drug: G‐Coat Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Coat Plus
Study: 28494595
Drug: Both G‐Coat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both G‐Coat Plus and Heliobond
Study: 21068008
Drug: L-4F administered
Normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-4F administered by intravenous (IV) infusion for 7 days
Study: 21068008
Drug: L-4F administered
Normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-4F administered by subcutaneous (SC) injection for 28 days
Study: 21068008
Drug: L-4F at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-4F at concentrations of 150, 375, or 1,000 ng/ml added to plasma ex vivo
Study: 11441198
Drug: Enalapril at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril at 10 mg/d (n=48)
Study: 8883531
Drug: iodixanol at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iodixanol at 270 mg I/ml (IOD-270)
Study: 8883531
Drug: iohexol at
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iohexol at 300 mg I/ml (IOH-300)
Study: 1562096
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg i.v. 10 min prior to intubation
Study: 1562096
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg i.m. 30 min prior to intubation
Study: 4056240
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of hydrocortisone (300 mg)
Study: 4056240
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of 20 mg of methylprednisolone, 4 mg of dexamethasone, or 4 mg of betamethasone
Study: 22734581
Drug: Paracetamol i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol i.v. 1 g
Study: 22734581
Drug: Paracetamol i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol i.v. 2 g
Study: 22734581
Drug: Oxycodone i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone i.v. (0.1 mg/kg)
Study: 19841862
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) for 6 weeks
Study: 2013244
Drug: Metronidazole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.5 g plus amikacin 500 mg i.v. 2 h before surgery and the same doses per 8 or 12 h for 2 days postoperatively (Group A)
Study: 2013244
Drug: Ornidazole 1
Normalized name: ornidazole 167 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole 1 g by intravenous infusion plus ceftriaxone 2 g i.v. 2 h before surgery and the same doses per 24 h for 2 days postoperatively (Group B)
Study: 24723147
Drug: Rivastigmine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (mean dose 5.1 ± 2.3 mg/day)
Study: 22287221
Drug: Two 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 8 Gy doses of external beam radiation
Study: 20481041
Drug: Imunofan combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imunofan combined with basic therapy
Study: 15012924
Drug: 3-month aerobic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month aerobic program above standard treatment
Study: 15012924
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without special advice for exercise
Study: 11603100
Drug: Keto acids/amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keto acids/amino acids (KA) supplementation at a dosage of 100 mg/kg/day
Study: 9587722
Drug: Bupivacaine-Midazolam (0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-Midazolam (0.125% bupivacaine 0.75 mL kg‐1 with 0.5% midazolam 50 micrograms kg‐1)
Study: 9587722
Drug: Bupivacaine-Morphine (0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-Morphine (0.125% bupivacaine 0.75 mL kg‐1 with 1% morphine chlorhydrate 0.05 mg kg‐1)
Study: 9587722
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (0.125% bupivacaine 0.75 mL kg‐1)
Study: 31004523
Drug: Oral function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral function intervention only
Study: 31004523
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral function plus nutritional intervention
Study: 28993388
Drug: Basic medication
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic medication reminder app group
Study: 28993388
Drug: Advanced medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced medication reminder app group
Study: 25778987
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of American ginseng (Panax quinquefolius)
Study: 2130002
Drug: Ceftriaxone 60-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 60-80 mg/kg/day intramuscularly for 5-7 days
Study: 2130002
Drug: Chloramphenicol 50-80
Normalized name: chloramphenicol 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 50-80 mg/kg/day orally in 4 divided doses for 12-14 days
Study: 371646
Drug: Intravenous mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mexiletine (150 mg bolus injection)
Study: 31535807
Drug: SpermActin Forte,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpermActin Forte, 1 sachet of 10 g once a day for 180 days
Study: 29217455
Drug: Monovision contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovision contact lenses without far prescription
Study: 26433727
Drug: Rapid clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapid clozapine titration (started at 25-50 mg, increased by 50-100 mg/day)